All News
Filter News
Found 297 articles
-
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
12/15/2022
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4 selective positive allosteric modulator, in adults living with schizophrenia in The Lancet.
-
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
12/14/2022
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that data from the pivotal Phase 3 (GEM-3) trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB) have been published here in the New England Journal of Medicine (NEJM).
-
Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.
-
As 2022 comes to its conclusion, the FDA has a handful of Prescription Drug User Fee Amendments still to wrap up. Here’s a look at that and more.
-
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
12/12/2022
Mirati Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for KRAZATI™, a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.
-
Mirati's KRAS Inhibitor Demonstrates Encouraging Clinical Profile in Latest Data Drop (Updated)
12/6/2022
Mirati's adagrasib demonstrated a solid safety profile in new data released Monday. Despite this, the company's stock fell 8% in after-hours trading. -
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
12/5/2022
Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc. announced that the company will participate in the investor-focused Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference, which is taking place in Miami on December 8.
-
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
12/5/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups.
-
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
12/1/2022
Krystal Biotech, Inc. a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced that the Company will participate in the BofA Securities 2022 Biotech SMID Cap Conference, which is taking place virtually from December 7-8.
-
Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
11/25/2022
Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1.
-
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
11/23/2022
Krystal Biotech, Inc. announced today that the Company will participate in the Evercore ISI 5th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1.
-
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
11/17/2022
Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301, an investigational gene-based treatment designed to address the underlying biology of aging skin for improvement of fine lines and wrinkles.
-
Freedom Biosciences Appoints Dr. David Hough as Chief Medical Officer
11/16/2022
Freedom Biosciences today announced the appointment of David Hough, MD, as Chief Medical Officer.
-
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
11/14/2022
Scholar Rock today reported financial results and corporate updates for the third quarter ended September 30, 2022.
-
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
11/9/2022
Scholar Rock today announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer.
-
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
11/8/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.
-
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
11/7/2022
Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today reported financial results and key operational progress updates for the third quarter ended September 30, 2022.
-
Dystrophic Epidermolysis Bullosa Treatment Market: Regional Outlook, Competitive Strategies & Forecast up to 2030 | Reports and Data
10/4/2022
The latest market analysis report published by Reports and Data, titled ‘Global Dystrophic Epidermolysis Bullosa Treatment Market – Forecast to 2030,’ thoroughly examines the Dystrophic Epidermolysis Bullosa Treatment industry to provide essential data & information for the targeted readers.
-
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
9/29/2022
Krystal Biotech, Inc. announced today that the Company will participate in the Chardan’s 6th Annual Genetic Medicines Conference in New York from October 3-4.
-
Increased Awareness of the Netherton Syndrome is Expected to Drive Netherton Syndrome Market Growth by 2030 | Reports and Data
9/28/2022
The latest market analysis report published by Reports and Data, titled ‘Global Netherton Syndrome Market – Forecast to 2030,’ thoroughly examines the Netherton Syndrome industry to provide essential data & information for the targeted readers